Trials / Completed
CompletedNCT00871559
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of REGN421 (SAR153192) in patients with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN421(SAR153192) |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2009-03-30
- Last updated
- 2014-03-26
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00871559. Inclusion in this directory is not an endorsement.